WallStreetZenWallStreetZen

NASDAQ: LXRX
Lexicon Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Lexicon Pharmaceuticals revenue was $31.08M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $26.6M, up 1,417.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LXRX annual revenue was $31.1M, with 2,481.5% growth year-over-year.

LXRX past revenue growth

How has LXRX's revenue growth performed historically?

Company
2,481.48%
Industry
497.69%
Market
20.68%
LXRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LXRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LXRX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

LXRX revenue history

Current Revenue
$31.1M
Current Earnings
-$200.4M
Current Profit Margin
-644.8%

Be the first to know when LXRX announces revenue.

LXRX Revenue History By Year

LXRX Yearly RevenueLXRX RevenueLXRX ChangeLXRX Revenue Growth
2024-12-31$31.08M$29.88M+2,481.48%
2023-12-31$1.20M$1.07M+766.19%
2022-12-31$139.00k-$159.00k-53.36%
2021-12-31$298.00k-$23.70M-98.76%
2020-12-31$24.00M-$298.08M-92.55%
2019-12-31$322.07M$258.86M+409.54%
2018-12-31$63.21M-$28.48M-31.06%
2017-12-31$91.69M$12.43M+15.69%
2016-12-31$79.26M-$50.76M-39.04%
2015-12-31$130.01M$107.16M+468.89%
2014-12-31$22.85M$20.63M+928.53%
2013-12-31$2.22M$1.13M+104.04%
2012-12-31$1.09M-$760.00k-41.10%
2011-12-31$1.85M-$3.06M-62.33%
2010-12-31$4.91M-$5.79M-54.13%
2009-12-31$10.70M-$21.62M-66.89%
2008-12-31$32.32M-$17.80M-35.51%
2007-12-31$50.12M-$22.68M-31.15%
2006-12-31$72.80M-$2.88M-3.81%
2005-12-31$75.68M$13.94M+22.58%
2004-12-31$61.74M$18.90M+44.12%
2003-12-31$42.84M$7.64M+21.70%
2002-12-31$35.20M$4.62M+15.12%
2001-12-31$30.58M$16.12M+111.47%
2000-12-31$14.46M$9.72M+205.17%
1999-12-31$4.74M$2.50M+111.34%
1998-12-31$2.24M$1.27M+131.66%
1997-12-31$967.74kN/AN/A

1 of 2

Lexicon Pharmaceuticals Revenue FAQ

What was LXRX's revenue last quarter?

On Invalid Date, Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 2024 revenue of $26.55 million up 3,682.62% year over year. In the same quarter last year, Lexicon Pharmaceuticals's revenue was $702.00 thousand.

What was Lexicon Pharmaceuticals's revenue in 2024?

Lexicon Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $31.08 million, a 2,481.48% increase year over year.

How much does Lexicon Pharmaceuticals make in a day?

Based on Lexicon Pharmaceuticals annual revenue for the past five years, LXRX makes an average of $31,077.81 per day.

What was Lexicon Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Lexicon Pharmaceuticals's revenue has grown 2,481.48% year over year. This is 1,983.78 percentage points higher than the US Biotechnology industry revenue growth rate of 497.69%. Lexicon Pharmaceuticals's revenue in the past year totaled $31.08 million.

How much does Lexicon Pharmaceuticals make in a year?

Lexicon Pharmaceuticals's revenue by year for the past five years is:
  • Lexicon Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $31.08 million, a 2,481.48% increase year over year.
  • Lexicon Pharmaceuticals's annual revenue for Dec 31, 2023 was $1.20 million, a 766.19% increase from 2022.
  • Lexicon Pharmaceuticals's annual revenue for 2022 was $139.00 thousand, a 53.36% decrease from 2021.
  • Lexicon Pharmaceuticals's annual revenue for 2021 was $298.00 thousand, a 98.76% decrease from 2020.
  • Lexicon Pharmaceuticals's annual revenue for 2020 was $24.00 million, a 92.55% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.